Phase III results put obinutuzumab in line for approval ...

A new study examined whether urinary biomarkers could predict future kidney complications in individuals with lupus nephritis ...

March is National Kidney Month, a time to shine a light on the thousands of individuals whose lives are deeply affected by ...

New findings from Spherix Global Insights’ Patient Chart Dynamix™: Lupus Nephritis (US), 2025 report reveal a treatment landscape in transition as specialists increasingly incorporate biologics, ...

A “living drug” was developed as a cancer treatment. Now it is showing promise for conditions, such as lupus and multiple sclerosis, that have long been considered incurable.

Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, today announced that its abstract detailing clinical results ongoing Phase 1/2 trial ...

Sara Moniuszko is a health and lifestyle reporter at CBSNews.com. Previously, she wrote for USA Today, where she was selected to help launch the newspaper's wellness vertical. She now covers breaking ...

This is the largest real-world analysis of mycophenolic acid in pediatric lupus nephritis to date, providing a decision-support system to help balance efficacy and safety.

For the millions of people living with lupus – a chronic autoimmune disease that can damage the kidneys, brain and other ...

Shontia Matlock shares her experience managing lupus and rheumatoid arthritis. Discover how she navigates treatment, faces emotional challenges, and advocates for herself.

Johnson & Johnson’s (J&J) nipocalimab, a potential immunoselective investigational treatment for adults with systemic lupus ...